Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

José Cunha-Vaz, WOC 2018 – Challenges and Recent Developments in DME

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 19th 2018

At WOC 2018, José Cunha-Vaz (University of Coimbra, Coimbra, Portugal) discussed his experience with treating patients with DME. The most significant developments in the area of DME are OCT imaging and the availability of anti-VEGF agents, which completely revolutionised treatment. The major issue is individualising treatment to each patient, as response varies greatly between different patients. The challenge is to understand how and which patients will respond to therapies. New drugs are currently on the horizon, which will offer new and better solutions to patients.

Questions:
1. What have been the most significant recent developments in the area of DME? (1:02)
2. Discuss the current unmet needs and/or the challenges you face when treating patients with DME. (2:00)
3. What developments are you most excited about in the area of DME over the next few years? (3:20)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup